Accessibility Menu

Ipsen(FRA) I7G

Market Cap€13.46BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPON/A
5 YearN/A
1 YearN/A
1 MonthN/A
€162.70
-3.79%
-6.40Today

Ipsen Financials at a Glance

Market Cap

€13.46BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

N/A

Net Income (TTM)

N/A

EPS (TTM)

€6.18

P/E Ratio

26.25

Dividend

€1.60

Beta (Volatility)

-0.02 (Low)

Price

€162.70

Volume

0

Open

€162.70

Previous Close

€162.70

Daily Range

€162.70 - €162.70

52-Week Range

€110.90 - €172.70

Estimated Earnings Date

N/A

I7G News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Ipsen

Ipsen SA manufactures pharmaceutical products for oncology, neuroscience, and rare diseases. It operates through the following segments: Specialty Care. The Specialty Care segment focuses on oncology with Somatuline, a somatostatin analog for the treatment of neuroendocrine tumors; Cabometyx, the single-agent treatment with significant improvement across all key efficacy endpoints in second-line renal cell carcinoma; Onivyde, a differentiated product with overall survival benefit addressing a high unmet medical need in pancreatic cancer; and Decapeptyl, an established and growing product in Europe and China for prostate cancer and rare diseases with Nutropin, a liquid formulation of recombinant human growth hormone and Increlex, a recombinant insulin-like growth factor of human origin. The company was founded by Henri Beaufour in 1929 and is headquartered in Boulogne-Billancourt, France.

Industry

Pharmaceuticals

Sector

Health Care

Employees

5,535

CEO

David G. Loew, MBA

Website

www.ipsen.com

I7G Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

11.47%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

3.81%

Dividend Yield

0.98%

Payout Ratio

N/A

Stock Overview

Market Cap

€13.46BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

82.71M

Volume

0

Avg. Volume

5.606

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Ipsen Performance Analysis

Ipsen annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31EUR 3,025,000,00014.4%
20232023-12-31EUR 3,127,500,0003.4%
20242024-12-31EUR 3,400,600,0008.7%
20252025-12-31EUR 3,675,900,0008.1%
Ipsen annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31EUR 7.810.6%
20232023-12-31EUR 7.73-1.0%
20242024-12-31EUR 4.15-46.3%
20252025-12-31EUR 5.3228.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
CurrentYOY CHG

Revenue

N/A

N/A

Gross Profit

N/A

N/A

Gross Margin

N/A

N/A

Market Cap

€13.46BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

N/A

N/A

Net Income

N/A

N/A

EBITDA

N/A

N/A

Quarterly Fundamentals

Name
CurrentYOY CHG

Total Cash

N/A

N/A

Total Debt

N/A

N/A

Accounts Receivable

N/A

N/A

Inventory

N/A

N/A

Long Term Debt

N/A

N/A

Short Term Debt

N/A

N/A

Return on Assets

N/A

N/A

Return on Invested Capital

N/A

N/A

Free Cash Flow

N/A

N/A

Operating Cash Flow

N/A

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,684.24-0.00%
^DJIDJI
$53,254.61-0.01%
^IXICNASDAQ
$26,319.55-0.00%
BTCBitcoin
$78,890.00-0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About I7G

What is the current price of Ipsen?

Ipsen is trading at €162.70 per share.

What is the 52-week range for Ipsen?

Over the past 52 weeks, Ipsen has traded between €110.90 and €172.70.

How much debt does Ipsen have?

As of the most recent reporting period, Ipsen reported total debt of €970.50M.

How much cash does Ipsen have on hand?

Ipsen reported €1.53B in cash and cash equivalents in its most recent financial results.

What is Ipsen’s dividend yield?

Ipsen currently has a dividend yield of 0.98%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services